Dr. Tam on Varying BTK Inhibitors in Mantle Cell Lymphoma

Publication
Video
Supplements and Featured PublicationsBTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1

Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, compares BTK inhibitors in mantle cell lymphoma (MCL).

For example, zanubrutinib in clinical use appears to have better tolerability compared with other BTK inhibitors, such as ibrutinib, explains Tam. Ongoing studies in other hematologic malignancies will further showcase the efficacy and safety of zanubrutinib in comparison to other BTK inhibitors.

The complete remission rates for zanubrutinib are encouraging, according to Tam, but since outcomes of zanubrutinib are being reported in 2 separate studies, it is difficult to compare definitively. Tam looks forward to seeing the long-term follow-up of zanubrutinib.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer